William Blair Has Positive Forecast for CVRx Q3 Earnings

Key Points

• William Blair has raised its Q3 2025 earnings estimate for CVRx to ($0.48) per share, an improvement from the previous estimate of ($0.49), and maintains a "Strong-Buy" rating on the stock.
• JPMorgan Chase downgraded its price target for CVRx from $15.00 to $7.00, while Cantor Fitzgerald set a higher target of $11.00, reflecting mixed market sentiments on the stock.
• CVRx recently reported a Q2 loss of ($0.57) per share, missing analysts' expectations, despite revenue surpassing estimates at $13.59 million.

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Equities researchers at William Blair upped their Q3 2025 earnings estimates for CVRx in a report issued on Tuesday, August 5th. William Blair analyst B. Vazquez now forecasts that the company will post earnings per share of ($0.48) for the quarter, up from their prior forecast of ($0.49). William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for CVRx's current full-year earnings is ($1.91) per share. William Blair also issued estimates for CVRx's Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.98) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.66) EPS.

CVRX has been the subject of several other research reports. JPMorgan Chase & Co. reaffirmed an "underweight" rating and set a $7.00 price objective (down previously from $15.00) on shares of CVRx in a report on Friday, May 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $11.00 price objective on shares of CVRx in a research note on Tuesday. Finally, Piper Sandler dropped their price objective on shares of CVRx from $20.00 to $12.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $14.00.

CVRx Stock Up 4.0%

CVRX stock opened at $7.07 on Thursday. The company has a 50-day moving average of $6.88 and a two-hundred day moving average of $9.49. The stock has a market capitalization of $184.39 million, a price-to-earnings ratio of -3.37 and a beta of 1.27. The company has a debt-to-equity ratio of 0.71, a current ratio of 14.82 and a quick ratio of 13.45. CVRx has a 52-week low of $4.30 and a 52-week high of $18.55.

CVRx (NASDAQ:CVRX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.05). The company had revenue of $13.59 million for the quarter, compared to analyst estimates of $13.22 million. CVRx had a negative net margin of 95.61% and a negative return on equity of 76.24%.

Institutional Trading of CVRx

Several institutional investors and hedge funds have recently bought and sold shares of CVRX. JPMorgan Chase & Co. increased its holdings in shares of CVRx by 10,520.1% in the 4th quarter. JPMorgan Chase & Co. now owns 628,286 shares of the company's stock worth $7,960,000 after buying an additional 622,370 shares during the last quarter. Norges Bank purchased a new stake in shares of CVRx in the 4th quarter worth about $1,411,000. Geode Capital Management LLC lifted its position in CVRx by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 323,931 shares of the company's stock valued at $4,105,000 after acquiring an additional 28,807 shares during the period. Trexquant Investment LP lifted its position in CVRx by 292.9% during the 4th quarter. Trexquant Investment LP now owns 102,197 shares of the company's stock valued at $1,295,000 after acquiring an additional 76,184 shares during the period. Finally, Wells Fargo & Company MN increased its stake in CVRx by 86.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,894 shares of the company's stock valued at $113,000 after purchasing an additional 4,115 shares in the last quarter. 75.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at CVRx

In other CVRx news, Director Kirk G. Nielsen purchased 10,966 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The shares were bought at an average cost of $5.45 per share, for a total transaction of $59,764.70. Following the purchase, the director owned 1,910,134 shares of the company's stock, valued at $10,410,230.30. This represents a 0.58% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have purchased 78,666 shares of company stock worth $411,031. Corporate insiders own 13.90% of the company's stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.